Celerion Inc. provides early clinical research services for pharmaceutical and biotechnology companies in the United States and internationally. The company focuses on delivering applied translational medicine to support early drug development decisions. Its services include global clinical research (Phase I and II, and NDA-enabling clinical pharmacology study conduct); clinical pharmacology sciences (modeling and simulation, study design and protocol development, clinical data sciences, biostatistics, pharmacokinetics/pharmacodynamics (PK/PD), and medical writing and reporting); global bioanalytical services (discovery to late stage services with capabilities in small and large drug, and me...
621 Rose Street
Lincoln, NE 68502-2040
Founded in 2010
Celerion Appoints Marc Hoffman as Chief Medical Officer
Feb 22 17
Celerion announced that Dr. Marc Hoffman has joined the company as Chief Medical Officer. Dr. Hoffman will have responsibility for leading the global medical staff and providing medical oversight and expertise to support early clinical research studies. Dr. Hoffman joins Celerion from Patient iP where he served as Chief Medical Officer, providing clinical leadership around Patient iP’s innovative platform, customer programs and related medical affairs activities. Dr. Hoffman brings over 28 years of knowledge and experience as a physician in the pharmaceutical, device, and CRO industries to this role.
Celerion Announces Celexus as a Premier Safety Reporting Tool for Phase I Clinical Trials
Nov 17 16
Celerion announced a key technology addition to its early clinical development capabilities, Celexus®. Celexus® offers clients a first look at their early clinical research data in real-time, as it is collected in the clinics and laboratories, from a first in class web-based portal. Celexus® is a sophisticated approach to viewing, analyzing and trending clinical data during acquisition. The viewable data includes screening, recruiting, adverse events, clinical laboratory, pharmacodynamics, pharmacokinetic and bioanalytical data. Celexus is directly populated with data from Clinquick®, Celerion's proprietary electronic data acquisition platform that captures source data directly from the clinic, eliminating the need for manual recording and transcription into a secondary electronic capture system. Designed specifically for clients' evolving needs, Celexus provides visual displays and the ability to define parameters to enable faster assessment of trends and identification of potential safety signals. Safety data visualizations include, among many others, vital signs, dosing, adverse events, ECGs and inclusion/exclusion criteria. These visualizations and source data are easily exported into multiple formats for analysis and creation of ad hoc reports. Another highlight of Celexus is the Key Performance Indicator Dashboard which displays the progression of the study with information such as recruitment, deviations, study milestones/timelines, dosing and retention.
Celerion Inc. Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
Celerion Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.